Mitsubishi Tanabe Submits NDA For Fifth DPP-4 Inhibitor In Japan
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma has submitted a new drug application for dipeptidyl peptidase-4 inhibitor teneligliptin in Japan